Karachi: Macter International Limited has announced the successful launch of Hepanox, an Enoxaparin Sodium Pre-filled syringe (PFS), according to a company report dated September 25, 2026. The introduction of this low molecular weight heparin (LMWH) anticoagulant signifies a noteworthy addition to the company's biopharmaceuticals portfolio and enhances its position within the anticoagulant therapeutic segment.

The launch, executed in compliance with Section 96 and 131 of the Securities Act, 2015 and Clause 5.6.1 of the Rule Book of Pakistan Stock Exchange Limited, marks a significant milestone for the company. It underscores Macter's strategic initiative to broaden its biopharmaceutical offerings, aligning with its long-term growth objectives and commitment to meeting evolving healthcare needs.

According to information available from the Pakistan Stock Exchange (PSX), the launch of Hepanox PFS is expected to play a crucial role in Macter's efforts to fortify its industry presence, particularly in the anticoagulant market. This development is part of Macter's continued dedication to expanding its product line to cater to diverse healthcare requirements.

The company's latest product initiative reflects Macter's ongoing resolve to support and enhance its contribution to the healthcare sector, with a focus on delivering effective therapeutic solutions.